Recent headlines have shown record patent filings, offensive assertions, and licensing deals created during this exciting and innovative time for the life sciences industry.

Protecting IP can be essential to attract funding or preventing competitors from unfairly competing with you. However, knowing how and when to build a robust IP portfolio can seem daunting. Here we will provide an overview of the IP issues facing new companies, together with a few recommendations. We will also provide opportunities to make this an interactive discussion and answer questions from the audience.

Register Here

About the Speaker:
Katherine Rubino | Partner and Director, Life Sciences Practice

Katie is a partner and chair of Caldwell’s life science practice group. Katie focuses on representing life sciences companies discovering, developing, protecting and offering pharmaceuticals, therapeutic vaccines, digital health, medical devices, biologics, and antibody products.

Katie has been featured in the Wall Street Journal, Fox Business, and Nature Biotechnology for her intellectual prowess in governing legal and scientific disputes. Katie specializes in transactions involving intellectual property rights, strategic partnerships, licensing, and research collaborations. In addition, she maintains an active practice in cross-border transactions, being dually qualified to practice in both the United States and England and Wales.

Katie is the chair of the Chemistry and the Law division of the American Chemical Society. She is a fixture of the entrepreneurial ecosystem and provides pro-bono legal advice in partnership with MIT Sandbox and Oregon Bioscience Incubator.